PMID- 12764232
OWN - NLM
STAT- MEDLINE
DCOM- 20030626
LR  - 20171116
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 34
IP  - 6
DP  - 2003 Jun
TI  - Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral 
      ischemia.
PG  - 1412-8
AB  - BACKGROUND AND PURPOSE: Inflammation and hypercoagulability contribute to the 
      development of acute cerebral ischemia. Both can be mediated by the CD40 system. 
      This study investigated whether the CD40 system and related mediators are 
      upregulated in patients with transient ischemic attack (TIA) or stroke. METHODS: 
      Seventeen patients with TIA, 60 patients with complete stroke, and 15 control 
      subjects were investigated. CD154 and P-selectin were analyzed on platelets and 
      CD40 on monocytes during and 3 months after acute cerebral ischemia by 
      double-label flow cytometry. Blood concentrations of soluble CD154 and monocyte 
      chemoattractant protein-1 (MCP-1) were evaluated. RESULTS: Our main findings are 
      as follows: (1) patients with acute cerebral ischemia showed a significant 
      increase of CD154 on platelets and CD40 on monocytes compared with controls; (2) 
      plasma levels of soluble CD154 were significantly higher in these patients; (3) 
      these patients had significantly higher numbers of prothrombotic 
      platelet-monocyte aggregates; (4) the chemoattractant MCP-1 was significantly 
      elevated in cerebral ischemia; and (5) at 3 months' follow-up, upregulation of 
      CD154 still persisted in patients with previous acute cerebral ischemia. 
      CONCLUSIONS: Patients with acute cerebral ischemia show upregulation of the CD40 
      system, which might contribute to the known proinflammatory, proatherogenic, and 
      prothrombotic milieu found in these patients.
FAU - Garlichs, C D
AU  - Garlichs CD
AD  - Medical Clinic II, Friedrich-Alexander-University Erlangen-Nuremberg, 
      David-Morgenstern-Weg 14, 91056 Erlangen, Germany. 
      Christoph.Garlichs@rzmail.uni-erlangen.de
FAU - Kozina, S
AU  - Kozina S
FAU - Fateh-Moghadam, S
AU  - Fateh-Moghadam S
FAU - Handschu, R
AU  - Handschu R
FAU - Tomandl, B
AU  - Tomandl B
FAU - Stumpf, C
AU  - Stumpf C
FAU - Eskafi, S
AU  - Eskafi S
FAU - Raaz, D
AU  - Raaz D
FAU - Schmeisser, A
AU  - Schmeisser A
FAU - Yilmaz, A
AU  - Yilmaz A
FAU - Ludwig, J
AU  - Ludwig J
FAU - Neundorfer, B
AU  - Neundorfer B
FAU - Daniel, W G
AU  - Daniel WG
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20030522
PL  - United States
TA  - Stroke
JT  - Stroke
JID - 0235266
RN  - 0 (Biomarkers)
RN  - 0 (CD40 Antigens)
RN  - 0 (Chemokine CCL2)
RN  - 0 (P-Selectin)
RN  - 0 (Receptors, Interleukin-2)
RN  - 147205-72-9 (CD40 Ligand)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
EIN - Stroke. 2003 Jul;34(7):1820
CIN - Stroke. 2003 Jun;34(6):1417-8. PMID: 12764236
MH  - Acute Disease
MH  - Biomarkers/analysis/blood
MH  - Blood Platelets/metabolism
MH  - Brain Ischemia/blood/*physiopathology
MH  - C-Reactive Protein/analysis
MH  - CD4-Positive T-Lymphocytes/metabolism
MH  - CD40 Antigens/*metabolism
MH  - CD40 Ligand/blood/*metabolism
MH  - Cell Count
MH  - Chemokine CCL2/blood
MH  - Female
MH  - Flow Cytometry
MH  - Follow-Up Studies
MH  - Humans
MH  - Ischemic Attack, Transient/blood/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Monocytes/metabolism
MH  - P-Selectin/metabolism
MH  - Platelet Adhesiveness
MH  - Receptors, Interleukin-2/biosynthesis
MH  - Reference Values
MH  - Up-Regulation
EDAT- 2003/05/24 05:00
MHDA- 2003/06/27 05:00
CRDT- 2003/05/24 05:00
PHST- 2003/05/24 05:00 [pubmed]
PHST- 2003/06/27 05:00 [medline]
PHST- 2003/05/24 05:00 [entrez]
AID - 01.STR.0000074032.64049.47 [pii]
AID - 10.1161/01.STR.0000074032.64049.47 [doi]
PST - ppublish
SO  - Stroke. 2003 Jun;34(6):1412-8. doi: 10.1161/01.STR.0000074032.64049.47. Epub 2003 
      May 22.